M & A
“Four or five major acquisitions over the last few years repositioned it, a 140-year-old company, from being a B-to-B company to B-to B-to-C company. That is a major enterprise strategy shift,” says CEO Patrick Lockwood-Taylor.
“In a very siloed organization made up of a jigsaw of different companies, no one was thinking enterprise first,” says Perrigo CEO Patrick Lockwood-Taylor. “The fundamentals of running operations, brand-building, innovation, they are now as they were.”
At opening session of CHPA’s annual Self-Care Leadership Summit on March 17 in Orlando, it presented Fuad Sawaya its highest honor named for Ivan Combe, an industry pioneer who served on its board from 1958 until 2000.
Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.
As the Danish vaccine maker plots further M&A activity.
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Brazil’s EMS has agreed to acquire Sanofi’s Medley generics business in a deal aimed at strengthening its position in the country’s off-patent medicines market, with the combined platform potentially reaching about 32% share pending regulatory approval.
Investment bankers, advisors and a former CEO shared their insights at BIO’s Investor and Growth Summit about large and mid-sized pharma deal appetites, noting it’s not all about patent cliffs.
Big pharma R&D and business development leaders at Biocom’s Global Partnering and Investor Conference commented on industry headwinds and tailwinds, how to pitch a platform deal and other dealmaking tips.
“Infant formula has consumed cash” and “at the end of the day, we need to be committed to improve our cash flow,” says CFO Eduardo Bezerra as Perrigo continues reviewing it options for the business.
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
The spotlight remains firmly on the French biotech’s prized inflammatory bowel disease asset.